Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

Isamu Okamoto • Keisuke Aoe • Terufumi Kato • Yukio Hosomi • Akira Yokoyama •
Fumio Imamura • Katsuyuki Kiura • Tomonori Hirashima • Makoto Nishio • Naoyuki Nogami •
Hiroaki Okamoto • Hideo Saka • Nobuyuki Yamamoto • Naoto Yoshizuka • Risa Sekiguchi •
Kazuhiro Kiyosawa • Kazuhiko Nakagawa • Tomohide Tamura

Published online: 2 August 2013
© Springer Science+Business Media New York 2013

Erratum to: Invest New Drugs DOI 10.1007/s10637-013-9941-z

The original version of this article unfortunately contains some errors in the text describing the incidences of toxicities. The correct text is given below:

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-013-9941-z>.

I. Okamoto (✉) • K. Nakagawa
Department of Medical Oncology,
Kinki University Faculty of Medicine, 377-2 Ohno-higashi,
Osaka-Sayama, Osaka 589-8511, Japan
e-mail: chi-okamoto@dotd.med.kindai.ac.jp

K. Aoe
National Hospital Organization Yamaguchi-Ube Medical Center,
Yamaguchi, Japan

T. Kato
Kanagawa Cardiovascular and Respiratory Center,
Kanagawa, Japan

Y. Hosomi
Tokyo Metropolitan Cancer and Infectious Diseases
Center Komagome Hospital, Tokyo, Japan

A. Yokoyama
Niigata Cancer Center Hospital, Niigata, Japan

F. Imamura
Osaka Medical Center for Cancer and Cardiovascular Diseases,
Osaka, Japan

K. Kiura
Okayama University Hospital, Okayama, Japan

Safety

All 109 patients who received the initial combination therapy were assessable for safety analysis. The major adverse events for each treatment period (entire, initial combination, and maintenance periods) are shown in Table 3. Hematologic

T. Hirashima
Osaka Prefectural Medical Center for Respiratory and Allergic
Diseases, Osaka, Japan

M. Nishio
Cancer Institute Hospital of Japanese Foundation for Cancer
Research, Tokyo, Japan

N. Nogami
National Hospital Organization Shikoku Cancer Center,
Ehime, Japan

H. Okamoto
Yokohama Municipal Citizen's Hospital, Kanagawa, Japan

H. Saka
National Hospital Organization Nagoya Medical Center,
Aichi, Japan

N. Yamamoto
Shizuoka Cancer Center, Shizuoka, Japan

N. Yoshizuka • R. Sekiguchi • K. Kiyosawa
Eli Lilly Japan K.K., Hyogo, Japan

T. Tamura
National Cancer Center Hospital, Tokyo, Japan

toxicities reaching $\geq$ grade 3 were neutropenia (56.9 %), thrombocytopenia (41.3 %), anemia (31.2 %), and leukopenia (22.0 %). Nonhematologic toxicities observed in more than half of patients included appetite loss (75.2 %), nausea (74.3 %), fatigue (67.9 %), and ALT increased (51.4 %), but the incidence of toxicities of grade 3 or higher was less than 10 %. The majority of adverse events were observed during the initial 4 cycles of pemetrexed and

carboplatin combination therapy. Common toxicities $\geq$ grade 3 observed in the maintenance period were similar to those observed during the initial combination treatment period, including neutropenia (40.0 %), thrombocytopenia (16.7 %), leukopenia (11.7 %), and anemia (13.3 %). Newly emerged or deteriorated toxicities during maintenance periods were rarely observed. No treatment-related deaths were reported in this study.